Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study

McNeill, S. Alan; Hargreave, T. B.; Roehrborn, Claus G.

doi:10.1016/j.urology.2004.07.042

Cited by 94 publications

(52 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirdly, the length of time to first trial of voiding in our group is possibly too long. Longer catheterisation time has been demonstrated to have no benefit towards the rate of successful TWOC when compared to the data over shorter periods [9] . Our institute has since changed its policy for the time to TWOC following catheterisation.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Management Outcome of Acute Urinary Retention

et al. 2009

View full text Add to dashboard Cite

Objectives: To assess for predictors of outcome in patients presenting with acute urinary retention (AUR). Methods: A study was performed in our unit to evaluate trial without catheter (TWOC) and successive management. We assessed for predictors of surgical or medical management, which included: age, volume drained at time of catheterisation, cause of retention, serum creatinine, success of trial of voiding, co-morbidities, prostate-specific antigen (PSA) and prostate size on digital rectal examination (DRE). Results: 72 men were entered into the study over an 18-month period: 27 had a successful first TWOC, 20 patients had a second TWOC, and 6 were successful. In total, 31 of the 33 patients with a successful TWOC remained on α-blockers without a further episode of AUR within a minimum of 6 months’ follow-up. Patients failing TWOC were managed by transurethral resection of the prostate (n = 22), long-term catheterisation (n = 15) or prostatic stents (n = 3), and 1 patient died prior to intervention. Three predictors were significant on multivariate analysis: PSA (>2.9 ng/ml), prostate size on DRE (large) and volume drained at time of catheterisation (≥1,000 ml). Conclusion: Patients with elevated PSA (>2.9 ng/ml), a large prostate size on DRE and a volume drained at time of catheterisation >1,000 ml are best managed by surgical intervention, while those with volumes drained at time of catheterisation of <1,000 ml, a PSA ≤2.9 ng/ml, and moderate to small prostate on DRE may be managed medically.

show abstract

Section: Discussionmentioning

confidence: 92%

“…The standard rate of successful trial of voiding is approximately 45%, from reviewing the literature [9][10][11][12] . In our study, 43% had a successful trial of voiding.…”

Section: Discussionmentioning

confidence: 99%

Management Outcome of Acute Urinary Retention

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The time at which patient was considered as a medical failure was analyzed using the Kaplan-Meier approach, as suggested by McNeil et al [4]. To assess the effects of different variables on the long-term outcome of patients, logistic regression was performed.…”

Section: Exclusion Criteriamentioning

confidence: 99%

Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia

Chan

Wong

et al. 2009

Int Urol Nephrol

View full text Add to dashboard Cite

Although AR blockers increased the success rate of TWOC, approximately half of the patients in this study still required additional intervention within five years. By using appropriate selection criteria, such as a large prostate size (>50 ml) or high serum PSA level during AUR (>10 microg/l), patients who are at greater risk of TWOC failure can be identified, and earlier surgical intervention can be offered to them.

show abstract

“…Another study with doxazosin [7] reporting 82% efficacy only evaluated symptoms, patient age, prostate volume and spontaneous micturition. The number of patients with a new AUR episode over the middle term was not specified, and the study design even doubled the drug dose to rescue more patients who recover micturitionwithout assessing the situation over the long term.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Doxazosin in the Treatment of Acute Urinary Retention due to Benign Prostate Hyperplasia

Prieto

Romero²,

López³

et al. 2008

Urol Int

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH). An evaluation is made of the number of patients recovering spontaneous micturition after catheter removal, micturition quality, and the number of patients suffering new AUR episodes or who require surgery in the 2 years following the first episode. Patients and Methods: A randomized, controlled study in males with AUR secondary to BPH. Two groups are formed, administering modified-release doxazosin 4 mg to patients born in even-numbered years, once a day in the morning. Those born in odd-numbered years receive no medication. The catheter is withdrawn 1 month later. Flowmetry is performed, with determination of ultrasonographic postmicturition retention at withdrawal, and after 6, 12 and 24 months. Results: Of the 65 patients included, 47 proved evaluable, and 46 complied with treatment (with exclusion of 1 case due to hypotension). Of the 22 patients treated with doxazosin, 15 (68.86%) presented AUR after 2 years, while 7 (31.2%) showed spontaneous micturition. Of the 24 patients treated with bladder catheterization in the absence of medication, 16 (66.6%) presented AUR after the same period of time, while 8 (33.3%) showed spontaneous micturition. There were no statistically significant differences between the treated and untreated subjects in terms of drug efficacy. Residual flow parameters are described in the population with spontaneous micturition in each stage of the study. Conclusion: In our series, treatment with the α-blocker doxazosin (4 mg, modified-release formulation), added to bladder catheterization, showed no increased efficacy in AUR treatment versus catheterization alone. Two years after the urinary retention episode, 31.2% of the patients treated with modified-release doxazosin 4 mg, and 33.3% of those with a bladder catheter only were seen to maintain spontaneous micturition.

show abstract

Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study

Cited by 94 publications

References 14 publications

Management Outcome of Acute Urinary Retention

Management Outcome of Acute Urinary Retention

Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia

Efficacy of Doxazosin in the Treatment of Acute Urinary Retention due to Benign Prostate Hyperplasia

Contact Info

Product

Resources

About